Hemispherx Biopharma to Present Data on the Activity of Ampligen® Against Cancer at CHI’s 4th Annual Immuno-Oncology Summit, August 29 through September 2, 2016 in Boston, MA
August 29, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 29, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”), announced that it will present at CHI’s 4th Annual Immuno-Oncology...
A Hemispherx Biopharma anuncia um grande avanco: A aprovacão para comercializar o rintatolimode (nome comercial nos Estados Unidos: Ampligen®) para o tratamento de casos graves de Encefalomielite Miálgica/Síndrome da Fadiga Crônica (EM/SFC) na República Argentina
August 26, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
O primeiro produto aprovado indicado para EM/SFC em qualquer parte do mundo Essa aprovação inédita significa um caminho aberto para o crescimento na América Latina e União Europeia ...
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
August 26, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 26, 2016 (GLOBE...
Hemispherx Biopharma anuncia un logro importante: aprobación de rintatolimod para la venta comercial (nombre comercial en EE. UU.: Ampligen®) para el tratamiento de casos severos de encefalomielitis miálgica/síndrome de fatiga crónica (EM/SFC) en la República Argentina
August 26, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
Primer producto aprobado para la indicación EM/SFC en todo el mundo Esta nueva aprobación abre paso para el crecimiento en Latinoamérica y la Unión Europea PHILADELPHIA, Aug. 26, 2016 (GLOBE...
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
August 26, 2016 01:00 ET
|
Hemispherx Biopharma, Inc.
First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 26, 2016 (GLOBE...
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
August 25, 2016 20:30 ET
|
Hemispherx Biopharma, Inc.
First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 25, 2016 (GLOBE...
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
August 24, 2016 10:03 ET
|
Hemispherx Biopharma, Inc.
First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 24, 2016 (GLOBE...
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
August 23, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 23, 2016 (GLOBE...
Hemispherx Biopharma Forms Scientific Advisory Board to Provide Additional Scientific and Pharmaceutical Expertise
August 19, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 19, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that it has formed a scientific advisory board (SAB). The purpose of the SAB is to leverage its...
Hemispherx Biopharma Announces 1-for-12 Reverse Stock Split
August 17, 2016 16:15 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 17, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) (the “Company), announced today that it will effect a 1-for-12 reverse stock split of its common stock. At the...